Takeda Pharmaceutical (NYSE:TAK) Sees Unusually-High Trading Volume - What's Next?

Key Points

• Takeda Pharmaceutical experienced a dramatic increase in trading volume, with about 8.85 million shares changing hands, marking a 292% rise from the previous day's volume.
• Morgan Stanley upgraded Takeda’s rating from "equal weight" to "overweight," indicating a more favorable outlook for the company's stock.
• In its latest earnings report, Takeda missed consensus estimates, reporting $0.16 EPS against a projected $0.24 and revenue of $7.34 billion compared to an expected $8.02 billion.

Shares of Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) saw strong trading volume on Wednesday . 8,851,016 shares were traded during mid-day trading, an increase of 292% from the previous session's volume of 2,258,672 shares.The stock last traded at $13.55 and had previously closed at $14.32.

Takeda Pharmaceutical Stock Up 3.3%

The firm's 50 day moving average price is $14.86 and its 200-day moving average price is $14.52. The company has a current ratio of 1.16, a quick ratio of 0.52 and a debt-to-equity ratio of 0.60. The company has a market cap of $45.09 billion, a P/E ratio of 47.23 and a beta of 0.22.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. The company had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. As a group, equities research analysts expect that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Institutional Investors Weigh In On Takeda Pharmaceutical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC bought a new stake in shares of Takeda Pharmaceutical during the 1st quarter worth approximately $37,000. Farther Finance Advisors LLC increased its holdings in Takeda Pharmaceutical by 29.2% during the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock worth $69,000 after buying an additional 1,045 shares during the last quarter. Fifth Third Bancorp raised its position in Takeda Pharmaceutical by 85.5% during the first quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock worth $78,000 after acquiring an additional 2,411 shares in the last quarter. Point72 Hong Kong Ltd bought a new stake in Takeda Pharmaceutical during the fourth quarter worth $94,000. Finally, GAMMA Investing LLC lifted its stake in Takeda Pharmaceutical by 22.6% in the first quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock valued at $105,000 after acquiring an additional 1,296 shares during the last quarter. 9.17% of the stock is owned by institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.